FDA pushes review date for Biogen blood drug

Share this article:

FDA extended the review time for Biogen Idec's Alprolix, a candidate for hemophilia B, by three months, the company said today. The biotech added that it submitted “additional information related to the validation of a manufacturing step for Alprolix,” and due to the timing of that submission, the agency extended its PDUFA date to allow more time to review. Hemophilia B is a rare, inherited disorder that impairs the blood's ability to clot. Alprolix is also under review in Canada, Australia and Japan. Biogen Idec also has a long-acting recombinant coagulation factor pending approval for the treatment of hemophilia A. That drug, to be sold under the name Eloctate, was also delayed 90 days; its PDUFA date is coming up in 1Q14. Both products have orphan-drug status in the US.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.